More topics

Limited coverage drugs – ixekizumab

Last updated on February 21, 2025

Generic name:

ixekizumab

Strength:

80 mg/1 mL

Form:

solution for subcutaneous injection in a pre-filled syringe or pre-filled auto-injector

Special Authority criteria

Approval period

For the treatment of moderate to severe plaque psoriasis, according to criteria detailed in HLTH 5380, when a Special Authority request is submitted by a dermatologist.

First approval: 12 weeks

Renewal: 1 year

For the treatment of moderate to severe psoriatic arthritis, according to criteria detailed in HLTH 5360 (Initial/Switch) or HLTH 5361 (renewal), when a Special Authority is submitted by a rheumatologist.

First approval: 1 year

Renewal: 1 year

Practitioner exemptions

  • No practitioner exemptions.

Special notes

  • PharmaCare covers a maximum of 28 days per fill for ixekizumab.

Special Authority request form(s)